Use of taurolidine to treat tumors
View Patent ↗The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
1. A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurolidine or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.
2. The method of claim 1 , wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.
3. The method of claim 1 , wherein said composition is administered by intraperitoneal lavage.
4. The method of claim 1 , wherein said composition is administered systematically.
5. The method of claim 4 , wherein said composition is administered intravenously.
6. The method of claim 1 , wherein said composition comprises taurolidine.
7. The method of claim 1 , wherein said composition comprises a taurolidine derivative or metabolite.
8. The method of claim 1 , further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
9. A method of inhibiting growth of a recurrent autologous tumor in a mammal, comprising administering to said mammal after therapeutic intervention for a primary tumor a composition comprising taurultam or a biologically active derivative thereof, in an amount sufficient to induce tumor cell death by apoptosis, wherein said tumor is ovarian cancer.
10. The method of claim 9 , wherein said composition is administered to directly contact the surface of a cell of said recurrent tumor.
11. The method of claim 9 , wherein said composition is administered by intraperitoneal lavage.
12. The method of claim 9 , wherein said composition is administered systematically.
13. The method of claim 12 , wherein said composition is administered intravenously.
14. The method of claim 9 , wherein said composition comprises taurultam.
15. The method of claim 9 , wherein said composition comprises a taurultam derivative.
16. The method of claim 9 , further comprising administering a chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
17. The method of claim 1 , wherein said composition consists of taurolidine and a pharmaceutically acceptable excipient.
18. The method of claim 1 , wherein said composition consists of taurolidine, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.
19. The method of claim 18 , wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
20. The method of claim 9 , wherein said composition consists of taurultam and a pharmaceutically acceptable excipient.
21. The method of claim 1 , wherein said taurolidine is administered prophylactically at the time of surgery of said primary tumor.
22. The method of claim 9 , wherein said composition consists of taurultam, a chemotherapeutic agent, and a pharmaceutically acceptable excipient.
23. The method of claim 22 , wherein said chemotherapeutic agent selected from the group consisting of an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, an intercalating agent, a crosslinking agent, and an antibiotic.
24. The method of claim 9 , wherein said taurultam is administered. prophylactically at the time of surgery of said primary tumor.